Fig. 2: Comparison of MTB recommendations by the entity. | British Journal of Cancer

Fig. 2: Comparison of MTB recommendations by the entity.

From: Critical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a Comprehensive Cancer Centre

Fig. 2

a Recommendation frequency by cancer type. The percentage of patients receiving treatment recommendations by the MTB is indicated. b Percentage of patients receiving either single or multiple MTB recommendations. c Evidence level of primary treatment recommendation by entity as NCT/DKTK grade. CRC colorectal cancer, iCCA intrahepatic cholangiocarcinoma, PDAC pancreatic ductal adenocarcinoma, Ca cancer, CUP carcinoma of unknown primary, pCCA perihilar cholangiocarcinoma, NSCLC non-small cell lung cancer, HNSCC head and neck squamous cell cancer, HGSC high-grade serous carcinoma, HCC hepatocellular carcinoma, NEC neuroendocrine carcinoma.

Back to article page